Comparative Pharmacology
Head-to-head clinical analysis: DENDRID versus FUZEON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENDRID versus FUZEON.
DENDRID vs FUZEON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dendrid (idoxuridine) is a pyrimidine nucleoside analog that inhibits viral DNA replication by incorporating into viral DNA and inhibiting thymidylate synthetase, thereby blocking DNA synthesis.
Fusion inhibitor; binds to gp41 of HIV-1, preventing conformational changes required for fusion with host CD4+ T-cell membrane.
1.5 mg/kg IV every 8 hours; typical adult dose 100 mg IV every 8 hours.
90 mg subcutaneously twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged in renal impairment
Terminal elimination half-life: 3.8 hours; clinically, steady-state plasma concentrations are achieved within 2-3 days with subcutaneous administration
Primarily renal excretion; unchanged drug accounts for 70-90% of elimination; minor biliary/fecal excretion (<10%)
Renal: approximately 70% as unchanged drug via glomerular filtration; fecal: <5% as metabolites
Category C
Category C
Antiviral
Antiviral